BJCT-BIOJECT-needle less injection product Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BJCT-BIOJECT-needle less injection product

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: James Strauss who wrote (218)	7/11/1998 12:16:00 PM
From: Marc Kahn	Read Replies (1) of 534

Jim, This is the first that I have heard that "Next year's eps est are .31". By next year, do you mean FY99? Which analyst is projecting such a number? As of May 29, there were 27,218,758 shares outstanding. There are more shares outstanding now, after the exercise of warrants by Aries / Paramount and others. EPS of $.31 is at least a $8.4 million net profit. We have never come close to that number in annual revenue, and never shown a profit. The company is cutting costs by dampening its marketing efforts, so any radical increase in revenue from product sales is unlikely, unless a very active new alliance gets on line quickly. Another possibility is that we will get licensing revenue from a bunch of new partners. But, which analyst is privy to that information? I'm curious about where that number came from. Regards, Marc Kahn

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next